| ID Source | ID |
|---|---|
| PubMed CID | 68601 |
| CHEMBL ID | 537161 |
| CHEBI ID | 48556 |
| SCHEMBL ID | 204843 |
| MeSH ID | M0333581 |
| Synonym |
|---|
| AC-932 |
| mpv-785 |
| domitor |
| hydrochloride, medetomidine |
| mpv785 |
| medetomidine hydrochloride (usan) |
| D04883 |
| 86347-15-1 |
| CHEBI:48556 , |
| mpv 785 |
| medetomidine hydrochloride , |
| 4-[1-(2,3-dimethylphenyl)ethyl]-1h-imidazole hydrochloride |
| (+-)-4-(alpha,2,3-trimethylbenzyl)imidazole monohydrochloride |
| medetomidine hcl |
| CHEMBL537161 |
| zalopine |
| metomidine |
| dtxcid1025691 |
| cas-86347-15-1 |
| tox21_110966 |
| dtxsid3045691 , |
| AKOS015950971 |
| 1h-imidazole, 4-(1-(2,3-dimethylphenyl)ethyl)-, monohydrochloride, (+-)- |
| bh210p244u , |
| medetomidine hydrochloride [usan] |
| unii-bh210p244u |
| smr002533644 |
| MLS003882579 |
| FT-0630939 |
| FT-0645167 |
| AM20041260 |
| 106807-72-1 |
| S3060 |
| 4-(1-(2,3-dimethylphenyl)ethyl)-, monohydrochloride, (+/-)- |
| medetomidine hydrochloride [mart.] |
| medetomidine hydrochloride [mi] |
| (+/-)-4-(.alpha.,2,3-trimethylbenzyl)imidazole monohydrochloride |
| medetomidine hydrochloride [green book] |
| medetomidine (hydrochloride) |
| HY-17034B |
| VPNGEIHDPSLNMU-UHFFFAOYSA-N |
| (+/-)-5-[1-(2,3-dimethylphenyl)ethyl]-1h-imidazole hydrochloride |
| SCHEMBL204843 |
| AS-2748 |
| 4-(1-(2,3-dimethylphenyl)ethyl)-1h-imidazole hydrochloride |
| AKOS024458523 |
| 1h-imidazole, 4-[1-(2,3-dimethylphenyl)ethyl]-, monohydrochloride |
| domitor hydrochloride |
| 5-[1-(2,3-dimethylphenyl)ethyl]-1h-imidazole;hydrochloride |
| (s)-medetomidine hydrochloride |
| sr-01000597778 |
| SR-01000597778-1 |
| 5-(1-(2,3-dimethylphenyl)ethyl)-1h-imidazole hydrochloride |
| mfcd06798319 |
| SW219239-1 |
| (s)-4-(1-(2,3-dimethylphenyl)ethyl)-1h-imidazole hydrochloride;dexmedetomidine hydrochloride |
| FT-0670971 |
| BCP04768 |
| BCP04773 |
| medetomidin hydrochloride |
| Q27121262 |
| SB17477 |
| bdbm50230390 |
| 86347-15-1 (hcl) |
| CCG-266850 |
| levomedetomidine hcl |
| medetomidinehydrochloride |
| EN300-1696253 |
| 1h-imidazole, 4-[1-(2,3-dimethylphenyl)ethyl]-, hydrochloride (1:1) |
| M3314 |
| mfcd12912677 |
| SY059962 |
| medetomidine hydrochloride (mart.) |
| (+/-)-4-(alpha,2,3-trimethylbenzyl)imidazole monohydrochloride |
| placadine |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
| Class | Description |
|---|---|
| hydrochloride | A salt formally resulting from the reaction of hydrochloric acid with an organic base. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| TDP1 protein | Homo sapiens (human) | Potency | 28.2320 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 18.0308 | 0.0002 | 29.3054 | 16,493.5996 | AID743069; AID743075 |
| aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 11.8832 | 0.0007 | 23.0674 | 1,258.9301 | AID743085; AID743122 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 29.8493 | 0.0017 | 23.8393 | 78.1014 | AID743083 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Alpha-2A adrenergic receptor | Homo sapiens (human) | IC50 (µMol) | 3.3000 | 0.0000 | 1.4421 | 7.3470 | AID36186 |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | IC50 (µMol) | 3.3000 | 0.0000 | 1.2380 | 8.1590 | AID36186 |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | IC50 (µMol) | 3.3000 | 0.0000 | 1.4725 | 7.8980 | AID36186 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID226745 | Potency ratio is defined as IC50(medetomidine)/IC50(compound) | 1992 | Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4 | Synthesis and alpha-adrenergic activities of 2- and 4-substituted imidazoline and imidazole analogues. |
| AID36186 | Compound was evaluated for Adrenergic activity in Alpha-2 adrenergic receptor of human platelets | 1992 | Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4 | Synthesis and alpha-adrenergic activities of 2- and 4-substituted imidazoline and imidazole analogues. |
| AID36581 | Compound was evaluated for Adrenergic activity against Alpha-1 adrenergic receptor from rat aorta | 1992 | Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4 | Synthesis and alpha-adrenergic activities of 2- and 4-substituted imidazoline and imidazole analogues. |
| AID186232 | Percent maximal analogue response relative to phenylephrine =100% | 1992 | Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4 | Synthesis and alpha-adrenergic activities of 2- and 4-substituted imidazoline and imidazole analogues. |
| AID226744 | Potency ratio is defined as EC50 (medetomidine) / EC50 (compound) | 1992 | Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4 | Synthesis and alpha-adrenergic activities of 2- and 4-substituted imidazoline and imidazole analogues. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 3 (60.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (67.71) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||